Search results
Showing 1 to 13 of 13 results for cemiplimab
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)
Evidence-based recommendations on cemiplimab (Libtayo) for metastatic or locally advanced cutaneous squamous cell carcinoma in adults.
Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults.
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
NICE is unable to make a recommendation on cemiplimab (Libtayo) for treating recurrent or metastatic cervical cancer in adults because Sanofi did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA901
NICE is unable to make a recommendation on cemiplimab (Libtayo) for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer in adults. This is because Sanofi did not provide an evidence submission.
Show all sections
Sections for TA848
In development Reference number: GID-TA11869 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 19 February 2026.
See a complete list of all our guidance and quality standards currently open for consultation
Technology appraisal and highly specialised technologies appeals
Learn about the NICE Technology Appraisal and Highly Specialised Technologies appeals process, including how decisions are made, the criteria for appeals, and the role of the appeal panel in ensuring fair and transparent evaluations of health technologies.
Awaiting development Reference number: GID-TA11929 Expected publication date: TBC
In development Reference number: GID-TA11850 Expected publication date: 03 September 2026
Discontinued Reference number: GID-TA11289
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
In development Reference number: GID-TA10900 Expected publication date: TBC
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)
This guidance has been updated and replaced by NICE technology appraisal guidance TA802.